Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells

Endocrinology

Volumn 140, Issue 5, 1999, Pages 2134-2144

  Xu, Zhao Dong ^a   Oey, Lily ^a   Mohan, Subburaman ^b   Kawachi, Mark H ^a   Lee, Nan Sook ^a   Rossi, John J ^a   Yoko, Fujita Yamaguchi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RIBOZYME; SOMATOMEDIN B;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; RNA CLEAVAGE;

EID: 0033306815     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.5.6687     Document Type: Article

References (50)

1. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors
2. Molecular and cellular aspects of the insulin-like growth factor I receptor
3. Insulin-like growth factor II binding to the type I somatomedin receptor. Evidence for two high affinity binding sites
4. The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor
5. Binding of mutant of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6
6. Insulin-like growth factors 1 and 2, peptide messenger ribonucleic acid, gene structures and serum and tissue concentrations
7. Measurement of derivative of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia
8. Characterization of new monoclonal antibodies to human insulin-like growth factor-II and their application in Western immunoblot analysis
9. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors
10. Purification and characterization of a unique high molecular weight form of insulin-like growth factor II
11. The insulin-like growth factor-1 receptor: A key to tumor growth?
12. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis
13. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation
14. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant
15. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
16. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo
17. Insulin-like growth factor (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis
18. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
19. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I
20. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop
21. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)
22. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells
23. Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium
24. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis
25. 'Spontaneous' differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II
26. Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II
27. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid
28. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor
29. Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
30. Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice
31. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation
32. Suramin and serum insulin-like growth factor levels in metastatic cancer patients
33. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
34. Therapeutic ribozymes, principles and applications
35. Sequence of a cDNA clone encoding human preproinsulin-like growth factor II
36. Expression of small, therapeutic RNAs in human cell nuclei
37. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1
38. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction
39. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1
40. High-efficiency transformation of mammalian cells by plasmid DNA
41. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter
42. Importance of independence in ribozyme reactions: Kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus
43. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates
44. Quantitation of ribozyme target abundance by QCPCR
45. Protein enhancement of hammerhead ribozyme catalysis
46. An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis
47. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization
48. U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus
49. Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase
50. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor beta1 on programmed cell death through a p53- and IGF-independent mechanism